RXRX vs TEM: Which Is the Better Buy in 2026?
Last updated November 2026
Short answer
TEM is the larger of the two ($14.61B market cap): the incumbent the market prices for continued execution (-2,025.03x forward earnings, beta 3.61). RXRX is the smaller challenger ($2.23B), priced similarly on forward earnings (-4.33x): more room to run, but more to prove. The real question is which set of drivers you believe, and whether owning one (or both) leaves you over-concentrated.
RXRX vs TEM: the tie-breaker metrics
Same yardstick, side by side (as of November 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.
| Metric | RXRX | TEM | What it tells you |
|---|---|---|---|
| Market cap | $2.23B | $14.61B | Size. The larger name is the incumbent; the smaller has more room to grow and more to prove. |
| Forward P/E | -4.33 | -2,025.03 | Valuation on next year's expected earnings, the same yardstick for both. Lower is cheaper for that growth; higher means the market is paying up. |
| Beta | 1.15 | 3.61 | Volatility vs the market. Above 1 swings harder than the index; below 1 is steadier. Higher beta means bigger drawdowns to hold through. |
| Price vs 52-week range | 33% of range | 81% of range | Where today's price sits between the 52-week low and high. Near the high is momentum with less margin of safety; near the low is out of favor or a discount, depending on why. |
| Price / book | 2.21 | 29.13 | How much you pay over book value. Very high can signal an asset-light, high-return business or a rich price. |
Before you buy: how RXRX and TEM affect your concentration
The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. RXRX and TEM share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.
This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined RXRX and TEM exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.
What does Recursion Pharmaceuticals (RXRX) do?
Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Its platform combines automated wet-lab biology, high-throughput cellular imaging that generates petabytes of proprietary experimental data, and machine-learning models that map relationships between genes, compounds, and disease, layered with Exscientia's automated precision molecular design. Recursion intends to make money three ways: partnership and collaboration payments (upfront fees, research funding, and milestone payments from large pharma companies that use its platform), future royalties on any partnered drugs that reach market, and value from its own wholly owned pipeline of clinical candidates. Today the company is pre-revenue in the product sense: reported revenue is small (roughly $6.5 million in Q1 2026 and $7.7 million in Q2 2026) and comes mostly from partnerships rather than drug sales.
What does Tempus AI (TEM) do?
Tempus AI (NASDAQ: TEM) is a Chicago-based technology company that applies artificial intelligence to precision medicine, primarily in oncology but increasingly across cardiology, neuropsychiatry, and hereditary conditions. It operates two interconnected business lines: a diagnostics segment that performs next-generation sequencing (NGS), PCR profiling, molecular pathology, and hereditary genetic tests through CAP-accredited, CLIA-certified laboratories, charging on a per-test basis; and a Data and Applications segment that licenses de-identified, linked clinical, molecular, and imaging datasets to life sciences companies (Insights), offers clinical trial matching (Trials), and deploys AI-powered algorithm products for physicians (Algos) and an AI platform called Next. Approximately 95% of the top 20 pharmaceutical companies use Tempus data or trial services, and the platform has integrations across more than 7,000 physicians and hundreds of research partners, creating a self-reinforcing network where clinical volume generates data that improves AI models and attracts more customers.
RXRX vs TEM: how do they differ?
Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.
- RXRX drivers: An industrial-scale AI platform and proprietary data moat; A deep big-pharma partnership book.
- TEM drivers: Explosive Revenue Growth with a Clear Path to Profitability; Data Licensing as a High-Margin Flywheel.
Which fits which kind of investor
A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. A useful test is which set of risks you could hold through a drawdown: The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output. For TEM, tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%.
RXRX or TEM: which should you pick?
Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick RXRX if you believe its drivers more; TEM if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the RXRX and TEM guides.
RXRX vs TEM: the full fundamentals
RXRX. Because Recursion is pre-profit with minimal revenue, traditional earnings multiples do not apply, and the figures that matter most are cash on hand, the rate of cash burn, and how long the runway lasts before the company must raise money again. The October 2026 offering pushed the stated runway into 2029 at the cost of about 61.5 million new shares, while REC-4881 data and the Sanofi option added evidence on the pipeline side. Valuation is still a bet on future platform output and partnership milestones rather than on current financial performance, and Q3 2026 results are expected around November 4.
TEM. As of October 16, 2026, Tempus trades near $66 per share, roughly 8.3 times trailing revenue, a richer multiple than mid-2026 after the stock's summer rally. The P/E is not meaningful because the company is still loss-making on a trailing basis, and consensus still expects a small loss per share in 2027, though gross margin near 64 percent is at software-like levels. The analyst mean target is about $75, and third-quarter results on November 2, 2026 are the next checkpoint.
Headline figures (approximate, October 2026): RXRX shows revenue (q2 2026) ~$7.7 million (TTM ~$55 million, mostly partnership and milestone revenue), net loss (q2 2026) ~$131 million (TTM ~$519 million); EPS -$0.25 vs -$0.23 expected, cash ~$561 million on September 30, 2026 (preliminary), before ~$200 million of offering proceeds, stated cash runway Into 2029, including net proceeds of the October 2026 offering; TEM shows revenue (ttm) ~$1.43 billion, q2 2026 revenue (most recent quarter) ~$382 million (up ~22% YoY), gross margin (ttm) ~64%, operating margin (ttm) ~-20%.
The bottom line: RXRX vs TEM
RXRX and TEM are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined RXRX and TEM exposure against your real portfolio. It is not an investment adviser.
Wondering how RXRX or TEM fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.
Your questions about Recursion Pharmaceuticals
Ask Walnut's AI anything about RXRX and see how it fits what you own.
FAQ
What is the difference between RXRX and TEM?
+
Recursion Pharmaceuticals is a Salt Lake City-based, clinical-stage technology-enabled biopharmaceutical company that aims to industrialize drug discovery. Tempus AI (NASDAQ: TEM) is a Chicago-based technology company that applies artificial intelligence to precision medicine, primarily in oncology but increasingly across cardiology, neuropsychiatry, and hereditary conditions. They show up together because they share investment themes, but they are different businesses, so the better fit depends on which thesis you are expressing.
Is RXRX or TEM the better stock?
+
Neither is universally better. TEM is the larger incumbent; RXRX is the smaller challenger and looks pricier on forward earnings. Walnut is informational, not investment advice. Compare what each does, the tie-breaker metrics above, and the risks, then decide which fits your thesis and what you already own.
Which is cheaper, RXRX or TEM?
+
On forward P/E (as of November 2026), RXRX trades at -4.33x and TEM at -2,025.03x, so TEM is the cheaper of the two on next year's expected earnings. A lower multiple is not automatically the better buy: a richer valuation can be justified by faster growth, and a lower one can reflect real risk. Weigh the multiple against how fast each business is compounding.
Should you own both RXRX and TEM?
+
Because they share themes, owning both concentrates you in that theme. That can be intentional (a focused bet) or accidental (less diversification than it looks). Walnut can show your combined exposure across both, and whether adding either over-concentrates you, before you buy.
What are the risks of RXRX vs TEM?
+
RXRX: The central risk is that Recursion has no approved drug and remains deeply unprofitable, posting a net loss of roughly $131 million in Q2 2026 against only about $7.7 million of revenue, and about $519 million over the trailing twelve months, so the entire valuation rests on platform promise rather than proven output. AI-driven drug discovery as a category is still unproven at the finish line, and skeptics note that no AI-originated compound has yet delivered a blockbuster approval, leaving open the possibility that the platform advantage does not translate into clinical success. Early data such as the REC-4881 and REC-1245 results come from small, open-label studies, and Recursion's candidates could still fail in larger trials like most clinical-stage biotech assets do; even partnered programs depend on decisions outside Recursion's control. Dilution is not hypothetical: the October 2026 offering added about 61.5 million shares at $3.25, and although the company now guides to a cash runway into 2029, continued losses mean it may need to raise capital again. The stock has also been volatile, down about 42% over the past year and trading well below its 52-week high of about $7.18. TEM: Tempus remains unprofitable on a GAAP basis, with a full-year 2025 net loss of $245 million (which included $136 million in stock-based compensation), and the path to sustained GAAP profitability is long; Q1 2026 showed a net loss of $125.9 million, widening 85% year-over-year, and EPS missed analyst estimates by 34%. Reimbursement risk is material: a significant portion of Tempus's diagnostics revenue depends on favorable coverage decisions from CMS and private payers, and adverse rulings on NGS tests or laboratory-developed tests (LDTs) could reduce revenue per test sharply. Regulatory scrutiny of LDTs by the FDA, ongoing data privacy obligations under HIPAA, and the risk that competitors such as Guardant Health, Illumina, Roche, or PathAI develop comparable datasets or lower-priced tests could compress both volume growth and pricing power over time. The balance sheet carries about $1.44 billion of debt against roughly $816 million of cash as of mid-2026, and trailing operating cash flow was still negative at about $237 million. The stock has also been highly volatile in 2026, falling about 15 percent in the month to October 16 after a sharp summer rally.
Walnut is informational, not investment advice. This page is descriptive and not a recommendation to buy or sell RXRX or TEM; figures are approximate and dated (as of November 2026). Verify current data before investing.